nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitotane—FDX1—prostate gland—urinary bladder cancer	0.0271	0.161	CbGeAlD
Mitotane—FDX1—seminal vesicle—urinary bladder cancer	0.0229	0.136	CbGeAlD
Mitotane—FDX1—renal system—urinary bladder cancer	0.0185	0.11	CbGeAlD
Mitotane—FDX1—urethra—urinary bladder cancer	0.0181	0.108	CbGeAlD
Mitotane—FDX1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.018	0.0626	CbGpPWpGaD
Mitotane—FDX1—female reproductive system—urinary bladder cancer	0.0148	0.0877	CbGeAlD
Mitotane—FDX1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.0146	0.0508	CbGpPWpGaD
Mitotane—FDX1—vagina—urinary bladder cancer	0.0134	0.0793	CbGeAlD
Mitotane—CYP11B1—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0133	0.0466	CbGpPWpGaD
Mitotane—CYP11A1—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0114	0.0398	CbGpPWpGaD
Mitotane—FDX1—Biological oxidations—GSTZ1—urinary bladder cancer	0.0099	0.0346	CbGpPWpGaD
Mitotane—SHBG—prostate gland—urinary bladder cancer	0.00986	0.0585	CbGeAlD
Mitotane—FDX1—Biological oxidations—GSTO2—urinary bladder cancer	0.00939	0.0328	CbGpPWpGaD
Mitotane—FDX1—Biological oxidations—NAT1—urinary bladder cancer	0.00939	0.0328	CbGpPWpGaD
Mitotane—FDX1—lymph node—urinary bladder cancer	0.00864	0.0513	CbGeAlD
Mitotane—FDX1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00859	0.03	CbGpPWpGaD
Mitotane—SERPINA6—renal system—urinary bladder cancer	0.00797	0.0473	CbGeAlD
Mitotane—FDX1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00773	0.027	CbGpPWpGaD
Mitotane—CYP11A1—female reproductive system—urinary bladder cancer	0.00671	0.0399	CbGeAlD
Mitotane—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.0064	0.0223	CbGpPWpGaD
Mitotane—SERPINA6—female reproductive system—urinary bladder cancer	0.00639	0.0379	CbGeAlD
Mitotane—CYP11B1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00631	0.022	CbGpPWpGaD
Mitotane—CYP11A1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00547	0.0191	CbGpPWpGaD
Mitotane—CYP11A1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.0054	0.0188	CbGpPWpGaD
Mitotane—SHBG—female reproductive system—urinary bladder cancer	0.00538	0.0319	CbGeAlD
Mitotane—CYP11B1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00518	0.0181	CbGpPWpGaD
Mitotane—FDX1—Biological oxidations—NAT2—urinary bladder cancer	0.00514	0.0179	CbGpPWpGaD
Mitotane—SHBG—vagina—urinary bladder cancer	0.00487	0.0289	CbGeAlD
Mitotane—CYP11A1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00444	0.0155	CbGpPWpGaD
Mitotane—FDX1—Biological oxidations—HPGDS—urinary bladder cancer	0.00411	0.0143	CbGpPWpGaD
Mitotane—FDX1—Biological oxidations—GSTT1—urinary bladder cancer	0.00399	0.0139	CbGpPWpGaD
Mitotane—CYP11A1—lymph node—urinary bladder cancer	0.00393	0.0233	CbGeAlD
Mitotane—CYP11B1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00353	0.0123	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00348	0.0121	CbGpPWpGaD
Mitotane—SHBG—Nongenotropic Androgen signaling—SRC—urinary bladder cancer	0.00346	0.0121	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—GSTO2—urinary bladder cancer	0.00334	0.0117	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—NAT1—urinary bladder cancer	0.00334	0.0117	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.0033	0.0115	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00306	0.0107	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00302	0.0105	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00302	0.0105	CbGpPWpGaD
Mitotane—CYP11A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00298	0.0104	CbGpPWpGaD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00297	0.0104	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—GSTO2—urinary bladder cancer	0.00286	0.00998	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—NAT1—urinary bladder cancer	0.00286	0.00998	CbGpPWpGaD
Mitotane—CYP11A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00282	0.00985	CbGpPWpGaD
Mitotane—FDX1—Biological oxidations—GSTP1—urinary bladder cancer	0.00276	0.00965	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00275	0.00961	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00272	0.00948	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00262	0.00913	CbGpPWpGaD
Mitotane—CYP11A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00258	0.00901	CbGpPWpGaD
Mitotane—FDX1—Biological oxidations—GSTM1—urinary bladder cancer	0.00254	0.00887	CbGpPWpGaD
Mitotane—SHBG—Nongenotropic Androgen signaling—HRAS—urinary bladder cancer	0.00243	0.00849	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00236	0.00822	CbGpPWpGaD
Mitotane—CYP11A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00232	0.00811	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—NAT2—urinary bladder cancer	0.00183	0.00639	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00181	0.00631	CbGpPWpGaD
Mitotane—CYP11A1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.00176	0.00616	CbGpPWpGaD
Mitotane—FDX1—Metabolism—GSTZ1—urinary bladder cancer	0.00169	0.00591	CbGpPWpGaD
Mitotane—FDX1—Metabolism—NAT1—urinary bladder cancer	0.00161	0.0056	CbGpPWpGaD
Mitotane—FDX1—Metabolism—GSTO2—urinary bladder cancer	0.00161	0.0056	CbGpPWpGaD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.00158	0.00551	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—NAT2—urinary bladder cancer	0.00157	0.00547	CbGpPWpGaD
Mitotane—CYP11A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00155	0.0054	CbGpPWpGaD
Mitotane—FDX1—Metabolism—UGT2B7—urinary bladder cancer	0.00147	0.00512	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—HPGDS—urinary bladder cancer	0.00146	0.00511	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—GSTT1—urinary bladder cancer	0.00142	0.00496	CbGpPWpGaD
Mitotane—FDX1—Metabolism—CYP4B1—urinary bladder cancer	0.00132	0.00461	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—HPGDS—urinary bladder cancer	0.00125	0.00437	CbGpPWpGaD
Mitotane—FDX1—Metabolism—SLC19A1—urinary bladder cancer	0.00125	0.00436	CbGpPWpGaD
Mitotane—FDX1—Metabolism—PRSS3—urinary bladder cancer	0.00122	0.00425	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—GSTT1—urinary bladder cancer	0.00122	0.00424	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00106	0.00369	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—GSTP1—urinary bladder cancer	0.000985	0.00344	CbGpPWpGaD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000975	0.0034	CbGpPWpGaD
Mitotane—FDX1—Metabolism—TYMP—urinary bladder cancer	0.000973	0.00339	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000971	0.00339	CbGpPWpGaD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000934	0.00326	CbGpPWpGaD
Mitotane—CYP11B1—Corticotropin-releasing hormone—RHOA—urinary bladder cancer	0.00093	0.00324	CbGpPWpGaD
Mitotane—CYP11B1—Biological oxidations—GSTM1—urinary bladder cancer	0.000905	0.00316	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000905	0.00316	CbGpPWpGaD
Mitotane—CYP11B1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000893	0.00311	CbGpPWpGaD
Mitotane—FDX1—Metabolism—NAT2—urinary bladder cancer	0.00088	0.00307	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000842	0.00294	CbGpPWpGaD
Mitotane—CYP11A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000831	0.0029	CbGpPWpGaD
Mitotane—CYP11B1—Corticotropin-releasing hormone—CXCL8—urinary bladder cancer	0.000816	0.00285	CbGpPWpGaD
Mitotane—Confusional state—Fluorouracil—urinary bladder cancer	0.000815	0.00149	CcSEcCtD
Mitotane—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000806	0.00148	CcSEcCtD
Mitotane—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000805	0.00148	CcSEcCtD
Mitotane—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000805	0.00148	CcSEcCtD
Mitotane—Ataxia—Methotrexate—urinary bladder cancer	0.000804	0.00148	CcSEcCtD
Mitotane—Infection—Fluorouracil—urinary bladder cancer	0.000803	0.00147	CcSEcCtD
Mitotane—Osteoarthritis—Epirubicin—urinary bladder cancer	0.0008	0.00147	CcSEcCtD
Mitotane—Diplopia—Epirubicin—urinary bladder cancer	0.0008	0.00147	CcSEcCtD
Mitotane—Skin disorder—Gemcitabine—urinary bladder cancer	0.000798	0.00146	CcSEcCtD
Mitotane—CYP11A1—Corticotropin-releasing hormone—RHOA—urinary bladder cancer	0.000795	0.00278	CbGpPWpGaD
Mitotane—Anaemia—Etoposide—urinary bladder cancer	0.000795	0.00146	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000793	0.00146	CcSEcCtD
Mitotane—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000792	0.00145	CcSEcCtD
Mitotane—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000791	0.00145	CcSEcCtD
Mitotane—Anorexia—Gemcitabine—urinary bladder cancer	0.000783	0.00144	CcSEcCtD
Mitotane—CYP11B1—Corticotropin-releasing hormone—IL2—urinary bladder cancer	0.00078	0.00272	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000774	0.0027	CbGpPWpGaD
Mitotane—Breast disorder—Methotrexate—urinary bladder cancer	0.000773	0.00142	CcSEcCtD
Mitotane—Vertigo—Etoposide—urinary bladder cancer	0.000772	0.00142	CcSEcCtD
Mitotane—Body temperature increased—Thiotepa—urinary bladder cancer	0.000772	0.00142	CcSEcCtD
Mitotane—Anorexia—Fluorouracil—urinary bladder cancer	0.00077	0.00141	CcSEcCtD
Mitotane—Hypotension—Gemcitabine—urinary bladder cancer	0.000768	0.00141	CcSEcCtD
Mitotane—CYP11A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000764	0.00266	CbGpPWpGaD
Mitotane—Infection—Cisplatin—urinary bladder cancer	0.000761	0.0014	CcSEcCtD
Mitotane—FDX1—Metabolism—RRM2—urinary bladder cancer	0.000759	0.00265	CbGpPWpGaD
Mitotane—Lethargy—Doxorubicin—urinary bladder cancer	0.000756	0.00139	CcSEcCtD
Mitotane—Hypotension—Fluorouracil—urinary bladder cancer	0.000755	0.00139	CcSEcCtD
Mitotane—Ataxia—Epirubicin—urinary bladder cancer	0.000753	0.00138	CcSEcCtD
Mitotane—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000751	0.00138	CcSEcCtD
Mitotane—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00075	0.00138	CcSEcCtD
Mitotane—Skin disorder—Cisplatin—urinary bladder cancer	0.000744	0.00137	CcSEcCtD
Mitotane—Hypertension—Etoposide—urinary bladder cancer	0.000742	0.00136	CcSEcCtD
Mitotane—Diplopia—Doxorubicin—urinary bladder cancer	0.000741	0.00136	CcSEcCtD
Mitotane—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000741	0.00136	CcSEcCtD
Mitotane—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000738	0.00135	CcSEcCtD
Mitotane—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000731	0.00134	CcSEcCtD
Mitotane—Somnolence—Gemcitabine—urinary bladder cancer	0.000731	0.00134	CcSEcCtD
Mitotane—Anorexia—Cisplatin—urinary bladder cancer	0.00073	0.00134	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000727	0.00133	CcSEcCtD
Mitotane—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000726	0.00133	CcSEcCtD
Mitotane—Breast disorder—Epirubicin—urinary bladder cancer	0.000723	0.00133	CcSEcCtD
Mitotane—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00072	0.00132	CcSEcCtD
Mitotane—Somnolence—Fluorouracil—urinary bladder cancer	0.000718	0.00132	CcSEcCtD
Mitotane—Hypotension—Cisplatin—urinary bladder cancer	0.000716	0.00131	CcSEcCtD
Mitotane—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000714	0.00131	CcSEcCtD
Mitotane—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000711	0.0013	CcSEcCtD
Mitotane—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000709	0.0013	CcSEcCtD
Mitotane—Confusional state—Etoposide—urinary bladder cancer	0.000708	0.0013	CcSEcCtD
Mitotane—Muscular weakness—Epirubicin—urinary bladder cancer	0.000706	0.0013	CcSEcCtD
Mitotane—FDX1—Metabolism—HPGDS—urinary bladder cancer	0.000703	0.00245	CbGpPWpGaD
Mitotane—FDX1—Metabolism—ENO2—urinary bladder cancer	0.000703	0.00245	CbGpPWpGaD
Mitotane—Pain—Gemcitabine—urinary bladder cancer	0.000703	0.00129	CcSEcCtD
Mitotane—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000702	0.00129	CcSEcCtD
Mitotane—Asthenia—Thiotepa—urinary bladder cancer	0.000701	0.00129	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000699	0.00244	CbGpPWpGaD
Mitotane—CYP11A1—Corticotropin-releasing hormone—CXCL8—urinary bladder cancer	0.000698	0.00244	CbGpPWpGaD
Mitotane—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000698	0.00128	CcSEcCtD
Mitotane—Infection—Etoposide—urinary bladder cancer	0.000697	0.00128	CcSEcCtD
Mitotane—Ataxia—Doxorubicin—urinary bladder cancer	0.000696	0.00128	CcSEcCtD
Mitotane—Neutropenia—Methotrexate—urinary bladder cancer	0.000691	0.00127	CcSEcCtD
Mitotane—Pain—Fluorouracil—urinary bladder cancer	0.000691	0.00127	CcSEcCtD
Mitotane—Paraesthesia—Cisplatin—urinary bladder cancer	0.000688	0.00126	CcSEcCtD
Mitotane—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000687	0.00126	CcSEcCtD
Mitotane—FDX1—Metabolism—GSTT1—urinary bladder cancer	0.000682	0.00238	CbGpPWpGaD
Mitotane—Skin disorder—Etoposide—urinary bladder cancer	0.000682	0.00125	CcSEcCtD
Mitotane—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000677	0.00124	CcSEcCtD
Mitotane—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000676	0.00124	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000672	0.00234	CbGpPWpGaD
Mitotane—Breast disorder—Doxorubicin—urinary bladder cancer	0.000669	0.00123	CcSEcCtD
Mitotane—Anorexia—Etoposide—urinary bladder cancer	0.000669	0.00123	CcSEcCtD
Mitotane—Diarrhoea—Thiotepa—urinary bladder cancer	0.000668	0.00123	CcSEcCtD
Mitotane—CYP11A1—Corticotropin-releasing hormone—IL2—urinary bladder cancer	0.000667	0.00233	CbGpPWpGaD
Mitotane—Decreased appetite—Cisplatin—urinary bladder cancer	0.000666	0.00122	CcSEcCtD
Mitotane—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000666	0.00122	CcSEcCtD
Mitotane—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000661	0.00121	CcSEcCtD
Mitotane—Drowsiness—Methotrexate—urinary bladder cancer	0.000659	0.00121	CcSEcCtD
Mitotane—Infestation—Methotrexate—urinary bladder cancer	0.000659	0.00121	CcSEcCtD
Mitotane—Infestation NOS—Methotrexate—urinary bladder cancer	0.000659	0.00121	CcSEcCtD
Mitotane—Hypotension—Etoposide—urinary bladder cancer	0.000656	0.0012	CcSEcCtD
Mitotane—Pain—Cisplatin—urinary bladder cancer	0.000655	0.0012	CcSEcCtD
Mitotane—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000653	0.0012	CcSEcCtD
Mitotane—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00065	0.00119	CcSEcCtD
Mitotane—Neutropenia—Epirubicin—urinary bladder cancer	0.000647	0.00119	CcSEcCtD
Mitotane—Dizziness—Thiotepa—urinary bladder cancer	0.000646	0.00119	CcSEcCtD
Mitotane—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000639	0.00117	CcSEcCtD
Mitotane—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000631	0.00116	CcSEcCtD
Mitotane—Paraesthesia—Etoposide—urinary bladder cancer	0.00063	0.00116	CcSEcCtD
Mitotane—Haematuria—Methotrexate—urinary bladder cancer	0.000628	0.00115	CcSEcCtD
Mitotane—Somnolence—Etoposide—urinary bladder cancer	0.000624	0.00114	CcSEcCtD
Mitotane—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000623	0.00114	CcSEcCtD
Mitotane—Vomiting—Thiotepa—urinary bladder cancer	0.000621	0.00114	CcSEcCtD
Mitotane—Infestation—Epirubicin—urinary bladder cancer	0.000617	0.00113	CcSEcCtD
Mitotane—Infestation NOS—Epirubicin—urinary bladder cancer	0.000617	0.00113	CcSEcCtD
Mitotane—Drowsiness—Epirubicin—urinary bladder cancer	0.000617	0.00113	CcSEcCtD
Mitotane—Rash—Thiotepa—urinary bladder cancer	0.000616	0.00113	CcSEcCtD
Mitotane—Dermatitis—Thiotepa—urinary bladder cancer	0.000615	0.00113	CcSEcCtD
Mitotane—Headache—Thiotepa—urinary bladder cancer	0.000612	0.00112	CcSEcCtD
Mitotane—Decreased appetite—Etoposide—urinary bladder cancer	0.00061	0.00112	CcSEcCtD
Mitotane—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000606	0.00111	CcSEcCtD
Mitotane—Body temperature increased—Cisplatin—urinary bladder cancer	0.000605	0.00111	CcSEcCtD
Mitotane—CYP11B1—Metabolism—GSTZ1—urinary bladder cancer	0.000603	0.00211	CbGpPWpGaD
Mitotane—Pain—Etoposide—urinary bladder cancer	0.0006	0.0011	CcSEcCtD
Mitotane—Neutropenia—Doxorubicin—urinary bladder cancer	0.000598	0.0011	CcSEcCtD
Mitotane—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000595	0.00109	CcSEcCtD
Mitotane—Hepatitis—Methotrexate—urinary bladder cancer	0.000592	0.00109	CcSEcCtD
Mitotane—Asthenia—Gemcitabine—urinary bladder cancer	0.00059	0.00108	CcSEcCtD
Mitotane—Haematuria—Epirubicin—urinary bladder cancer	0.000588	0.00108	CcSEcCtD
Mitotane—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000584	0.00107	CcSEcCtD
Mitotane—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000583	0.00107	CcSEcCtD
Mitotane—Nausea—Thiotepa—urinary bladder cancer	0.00058	0.00106	CcSEcCtD
Mitotane—Urethral disorder—Methotrexate—urinary bladder cancer	0.00058	0.00106	CcSEcCtD
Mitotane—Feeling abnormal—Etoposide—urinary bladder cancer	0.000578	0.00106	CcSEcCtD
Mitotane—CYP11B1—Metabolism—GSTO2—urinary bladder cancer	0.000572	0.002	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—NAT1—urinary bladder cancer	0.000572	0.002	CbGpPWpGaD
Mitotane—Infestation—Doxorubicin—urinary bladder cancer	0.000571	0.00105	CcSEcCtD
Mitotane—Drowsiness—Doxorubicin—urinary bladder cancer	0.000571	0.00105	CcSEcCtD
Mitotane—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000571	0.00105	CcSEcCtD
Mitotane—Visual impairment—Methotrexate—urinary bladder cancer	0.00057	0.00105	CcSEcCtD
Mitotane—FDX1—Metabolism—NQO1—urinary bladder cancer	0.000567	0.00198	CbGpPWpGaD
Mitotane—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000564	0.00104	CcSEcCtD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000563	0.00196	CbGpPWpGaD
Mitotane—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000562	0.00103	CcSEcCtD
Mitotane—Body temperature increased—Etoposide—urinary bladder cancer	0.000555	0.00102	CcSEcCtD
Mitotane—Hepatitis—Epirubicin—urinary bladder cancer	0.000554	0.00102	CcSEcCtD
Mitotane—Eye disorder—Methotrexate—urinary bladder cancer	0.000553	0.00101	CcSEcCtD
Mitotane—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000553	0.00101	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.00055	0.00192	CbGpPWpGaD
Mitotane—Asthenia—Cisplatin—urinary bladder cancer	0.00055	0.00101	CcSEcCtD
Mitotane—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000547	0.001	CcSEcCtD
Mitotane—Haematuria—Doxorubicin—urinary bladder cancer	0.000544	0.000998	CcSEcCtD
Mitotane—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000544	0.000998	CcSEcCtD
Mitotane—Urethral disorder—Epirubicin—urinary bladder cancer	0.000543	0.000996	CcSEcCtD
Mitotane—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00054	0.00099	CcSEcCtD
Mitotane—Angiopathy—Methotrexate—urinary bladder cancer	0.000537	0.000985	CcSEcCtD
Mitotane—Dizziness—Fluorouracil—urinary bladder cancer	0.000534	0.00098	CcSEcCtD
Mitotane—Visual impairment—Epirubicin—urinary bladder cancer	0.000534	0.000979	CcSEcCtD
Mitotane—Diarrhoea—Cisplatin—urinary bladder cancer	0.000524	0.000962	CcSEcCtD
Mitotane—CYP11B1—Metabolism—UGT2B7—urinary bladder cancer	0.000523	0.00183	CbGpPWpGaD
Mitotane—Vomiting—Gemcitabine—urinary bladder cancer	0.000522	0.000959	CcSEcCtD
Mitotane—Mental disorder—Methotrexate—urinary bladder cancer	0.000518	0.000951	CcSEcCtD
Mitotane—Rash—Gemcitabine—urinary bladder cancer	0.000518	0.000951	CcSEcCtD
Mitotane—Dermatitis—Gemcitabine—urinary bladder cancer	0.000518	0.00095	CcSEcCtD
Mitotane—Eye disorder—Epirubicin—urinary bladder cancer	0.000517	0.000949	CcSEcCtD
Mitotane—Hypersensitivity—Etoposide—urinary bladder cancer	0.000517	0.000949	CcSEcCtD
Mitotane—CYP11A1—Metabolism—GSTZ1—urinary bladder cancer	0.000516	0.0018	CbGpPWpGaD
Mitotane—Malnutrition—Methotrexate—urinary bladder cancer	0.000515	0.000945	CcSEcCtD
Mitotane—Headache—Gemcitabine—urinary bladder cancer	0.000515	0.000945	CcSEcCtD
Mitotane—Flushing—Epirubicin—urinary bladder cancer	0.000514	0.000943	CcSEcCtD
Mitotane—Vomiting—Fluorouracil—urinary bladder cancer	0.000514	0.000943	CcSEcCtD
Mitotane—Hepatitis—Doxorubicin—urinary bladder cancer	0.000512	0.00094	CcSEcCtD
Mitotane—Rash—Fluorouracil—urinary bladder cancer	0.000509	0.000935	CcSEcCtD
Mitotane—Dermatitis—Fluorouracil—urinary bladder cancer	0.000509	0.000934	CcSEcCtD
Mitotane—Headache—Fluorouracil—urinary bladder cancer	0.000506	0.000929	CcSEcCtD
Mitotane—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000506	0.000928	CcSEcCtD
Mitotane—Dysgeusia—Methotrexate—urinary bladder cancer	0.000504	0.000925	CcSEcCtD
Mitotane—Asthenia—Etoposide—urinary bladder cancer	0.000503	0.000924	CcSEcCtD
Mitotane—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000503	0.000924	CcSEcCtD
Mitotane—Angiopathy—Epirubicin—urinary bladder cancer	0.000502	0.000922	CcSEcCtD
Mitotane—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000502	0.000921	CcSEcCtD
Mitotane—Visual impairment—Doxorubicin—urinary bladder cancer	0.000494	0.000906	CcSEcCtD
Mitotane—CYP11A1—Metabolism—GSTO2—urinary bladder cancer	0.000489	0.00171	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—NAT1—urinary bladder cancer	0.000489	0.00171	CbGpPWpGaD
Mitotane—Nausea—Gemcitabine—urinary bladder cancer	0.000488	0.000896	CcSEcCtD
Mitotane—Vomiting—Cisplatin—urinary bladder cancer	0.000487	0.000894	CcSEcCtD
Mitotane—Vision blurred—Methotrexate—urinary bladder cancer	0.000485	0.000891	CcSEcCtD
Mitotane—Mental disorder—Epirubicin—urinary bladder cancer	0.000485	0.00089	CcSEcCtD
Mitotane—Rash—Cisplatin—urinary bladder cancer	0.000483	0.000886	CcSEcCtD
Mitotane—Dermatitis—Cisplatin—urinary bladder cancer	0.000482	0.000885	CcSEcCtD
Mitotane—Malnutrition—Epirubicin—urinary bladder cancer	0.000482	0.000884	CcSEcCtD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000481	0.00168	CbGpPWpGaD
Mitotane—Diarrhoea—Etoposide—urinary bladder cancer	0.00048	0.000881	CcSEcCtD
Mitotane—Nausea—Fluorouracil—urinary bladder cancer	0.00048	0.000881	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.00048	0.00167	CbGpPWpGaD
Mitotane—Eye disorder—Doxorubicin—urinary bladder cancer	0.000479	0.000878	CcSEcCtD
Mitotane—Anaemia—Methotrexate—urinary bladder cancer	0.000476	0.000873	CcSEcCtD
Mitotane—Flushing—Doxorubicin—urinary bladder cancer	0.000475	0.000872	CcSEcCtD
Mitotane—FDX1—Metabolism—GSTP1—urinary bladder cancer	0.000473	0.00165	CbGpPWpGaD
Mitotane—Dysgeusia—Epirubicin—urinary bladder cancer	0.000472	0.000866	CcSEcCtD
Mitotane—CYP11B1—Metabolism—CYP4B1—urinary bladder cancer	0.000471	0.00164	CbGpPWpGaD
Mitotane—Angiopathy—Doxorubicin—urinary bladder cancer	0.000465	0.000853	CcSEcCtD
Mitotane—Dizziness—Etoposide—urinary bladder cancer	0.000464	0.000851	CcSEcCtD
Mitotane—Vertigo—Methotrexate—urinary bladder cancer	0.000463	0.000849	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000457	0.0016	CbGpPWpGaD
Mitotane—Nausea—Cisplatin—urinary bladder cancer	0.000455	0.000835	CcSEcCtD
Mitotane—Vision blurred—Epirubicin—urinary bladder cancer	0.000454	0.000833	CcSEcCtD
Mitotane—Mental disorder—Doxorubicin—urinary bladder cancer	0.000449	0.000823	CcSEcCtD
Mitotane—CYP11A1—Metabolism—UGT2B7—urinary bladder cancer	0.000447	0.00156	CbGpPWpGaD
Mitotane—Vomiting—Etoposide—urinary bladder cancer	0.000446	0.000819	CcSEcCtD
Mitotane—Malnutrition—Doxorubicin—urinary bladder cancer	0.000446	0.000818	CcSEcCtD
Mitotane—Anaemia—Epirubicin—urinary bladder cancer	0.000445	0.000817	CcSEcCtD
Mitotane—CYP11B1—Metabolism—SLC19A1—urinary bladder cancer	0.000445	0.00155	CbGpPWpGaD
Mitotane—Rash—Etoposide—urinary bladder cancer	0.000442	0.000812	CcSEcCtD
Mitotane—Dermatitis—Etoposide—urinary bladder cancer	0.000442	0.000811	CcSEcCtD
Mitotane—Headache—Etoposide—urinary bladder cancer	0.00044	0.000807	CcSEcCtD
Mitotane—FDX1—Metabolism—TYMS—urinary bladder cancer	0.000439	0.00153	CbGpPWpGaD
Mitotane—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000437	0.000801	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000435	0.000799	CcSEcCtD
Mitotane—FDX1—Metabolism—GSTM1—urinary bladder cancer	0.000434	0.00152	CbGpPWpGaD
Mitotane—FDX1—Metabolism—NCOR1—urinary bladder cancer	0.000434	0.00152	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PRSS3—urinary bladder cancer	0.000433	0.00151	CbGpPWpGaD
Mitotane—Vertigo—Epirubicin—urinary bladder cancer	0.000433	0.000794	CcSEcCtD
Mitotane—Confusional state—Methotrexate—urinary bladder cancer	0.000424	0.000778	CcSEcCtD
Mitotane—Vision blurred—Doxorubicin—urinary bladder cancer	0.00042	0.000771	CcSEcCtD
Mitotane—Infection—Methotrexate—urinary bladder cancer	0.000418	0.000766	CcSEcCtD
Mitotane—Nausea—Etoposide—urinary bladder cancer	0.000417	0.000765	CcSEcCtD
Mitotane—Hypertension—Epirubicin—urinary bladder cancer	0.000416	0.000763	CcSEcCtD
Mitotane—FDX1—Metabolism—GPX1—urinary bladder cancer	0.000416	0.00145	CbGpPWpGaD
Mitotane—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000412	0.000756	CcSEcCtD
Mitotane—Anaemia—Doxorubicin—urinary bladder cancer	0.000412	0.000756	CcSEcCtD
Mitotane—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000412	0.000755	CcSEcCtD
Mitotane—FDX1—Metabolism—ERCC2—urinary bladder cancer	0.000408	0.00143	CbGpPWpGaD
Mitotane—Skin disorder—Methotrexate—urinary bladder cancer	0.000408	0.000749	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000407	0.000748	CcSEcCtD
Mitotane—CYP11A1—Metabolism—CYP4B1—urinary bladder cancer	0.000403	0.00141	CbGpPWpGaD
Mitotane—Vertigo—Doxorubicin—urinary bladder cancer	0.000401	0.000735	CcSEcCtD
Mitotane—Anorexia—Methotrexate—urinary bladder cancer	0.000401	0.000735	CcSEcCtD
Mitotane—Confusional state—Epirubicin—urinary bladder cancer	0.000397	0.000728	CcSEcCtD
Mitotane—Hypotension—Methotrexate—urinary bladder cancer	0.000393	0.000721	CcSEcCtD
Mitotane—Infection—Epirubicin—urinary bladder cancer	0.000391	0.000717	CcSEcCtD
Mitotane—Shock—Epirubicin—urinary bladder cancer	0.000387	0.00071	CcSEcCtD
Mitotane—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000386	0.000708	CcSEcCtD
Mitotane—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000385	0.000707	CcSEcCtD
Mitotane—Hypertension—Doxorubicin—urinary bladder cancer	0.000385	0.000706	CcSEcCtD
Mitotane—FDX1—Metabolism—MTHFR—urinary bladder cancer	0.000384	0.00134	CbGpPWpGaD
Mitotane—Skin disorder—Epirubicin—urinary bladder cancer	0.000382	0.000701	CcSEcCtD
Mitotane—CYP11A1—Metabolism—SLC19A1—urinary bladder cancer	0.00038	0.00133	CbGpPWpGaD
Mitotane—Paraesthesia—Methotrexate—urinary bladder cancer	0.000377	0.000692	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000377	0.000692	CcSEcCtD
Mitotane—Anorexia—Epirubicin—urinary bladder cancer	0.000375	0.000688	CcSEcCtD
Mitotane—Somnolence—Methotrexate—urinary bladder cancer	0.000374	0.000686	CcSEcCtD
Mitotane—CYP11A1—Metabolism—PRSS3—urinary bladder cancer	0.000371	0.00129	CbGpPWpGaD
Mitotane—Dyspepsia—Methotrexate—urinary bladder cancer	0.00037	0.000679	CcSEcCtD
Mitotane—Hypotension—Epirubicin—urinary bladder cancer	0.000368	0.000674	CcSEcCtD
Mitotane—Confusional state—Doxorubicin—urinary bladder cancer	0.000367	0.000673	CcSEcCtD
Mitotane—Decreased appetite—Methotrexate—urinary bladder cancer	0.000365	0.00067	CcSEcCtD
Mitotane—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000363	0.000666	CcSEcCtD
Mitotane—Infection—Doxorubicin—urinary bladder cancer	0.000362	0.000663	CcSEcCtD
Mitotane—Pain—Methotrexate—urinary bladder cancer	0.000359	0.000659	CcSEcCtD
Mitotane—Shock—Doxorubicin—urinary bladder cancer	0.000358	0.000657	CcSEcCtD
Mitotane—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000357	0.000655	CcSEcCtD
Mitotane—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000356	0.000654	CcSEcCtD
Mitotane—Skin disorder—Doxorubicin—urinary bladder cancer	0.000354	0.000649	CcSEcCtD
Mitotane—Paraesthesia—Epirubicin—urinary bladder cancer	0.000353	0.000648	CcSEcCtD
Mitotane—Somnolence—Epirubicin—urinary bladder cancer	0.00035	0.000642	CcSEcCtD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000348	0.00121	CbGpPWpGaD
Mitotane—Anorexia—Doxorubicin—urinary bladder cancer	0.000347	0.000637	CcSEcCtD
Mitotane—CYP11B1—Metabolism—TYMP—urinary bladder cancer	0.000346	0.00121	CbGpPWpGaD
Mitotane—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000346	0.000635	CcSEcCtD
Mitotane—Dyspepsia—Epirubicin—urinary bladder cancer	0.000346	0.000635	CcSEcCtD
Mitotane—Decreased appetite—Epirubicin—urinary bladder cancer	0.000342	0.000627	CcSEcCtD
Mitotane—Hypotension—Doxorubicin—urinary bladder cancer	0.00034	0.000624	CcSEcCtD
Mitotane—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00034	0.000623	CcSEcCtD
Mitotane—Pain—Epirubicin—urinary bladder cancer	0.000336	0.000617	CcSEcCtD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000333	0.00116	CbGpPWpGaD
Mitotane—Body temperature increased—Methotrexate—urinary bladder cancer	0.000332	0.00061	CcSEcCtD
Mitotane—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000327	0.0006	CcSEcCtD
Mitotane—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000324	0.000595	CcSEcCtD
Mitotane—Somnolence—Doxorubicin—urinary bladder cancer	0.000324	0.000594	CcSEcCtD
Mitotane—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00032	0.000588	CcSEcCtD
Mitotane—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000316	0.00058	CcSEcCtD
Mitotane—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000314	0.000577	CcSEcCtD
Mitotane—CYP11B1—Metabolism—NAT2—urinary bladder cancer	0.000313	0.00109	CbGpPWpGaD
Mitotane—FDX1—Metabolism—PPARG—urinary bladder cancer	0.000311	0.00109	CbGpPWpGaD
Mitotane—Pain—Doxorubicin—urinary bladder cancer	0.000311	0.000571	CcSEcCtD
Mitotane—Body temperature increased—Epirubicin—urinary bladder cancer	0.000311	0.000571	CcSEcCtD
Mitotane—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00031	0.000568	CcSEcCtD
Mitotane—Asthenia—Methotrexate—urinary bladder cancer	0.000302	0.000553	CcSEcCtD
Mitotane—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.0003	0.00055	CcSEcCtD
Mitotane—FDX1—Metabolism—CREBBP—urinary bladder cancer	0.000299	0.00104	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000297	0.00104	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—TYMP—urinary bladder cancer	0.000296	0.00103	CbGpPWpGaD
Mitotane—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00029	0.000532	CcSEcCtD
Mitotane—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000288	0.000528	CcSEcCtD
Mitotane—Diarrhoea—Methotrexate—urinary bladder cancer	0.000288	0.000528	CcSEcCtD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000285	0.000994	CbGpPWpGaD
Mitotane—Asthenia—Epirubicin—urinary bladder cancer	0.000282	0.000518	CcSEcCtD
Mitotane—Dizziness—Methotrexate—urinary bladder cancer	0.000278	0.00051	CcSEcCtD
Mitotane—CYP11B1—Metabolism—RRM2—urinary bladder cancer	0.00027	0.000944	CbGpPWpGaD
Mitotane—Diarrhoea—Epirubicin—urinary bladder cancer	0.000269	0.000494	CcSEcCtD
Mitotane—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000268	0.000492	CcSEcCtD
Mitotane—CYP11A1—Metabolism—NAT2—urinary bladder cancer	0.000268	0.000936	CbGpPWpGaD
Mitotane—Vomiting—Methotrexate—urinary bladder cancer	0.000267	0.00049	CcSEcCtD
Mitotane—Rash—Methotrexate—urinary bladder cancer	0.000265	0.000486	CcSEcCtD
Mitotane—Dermatitis—Methotrexate—urinary bladder cancer	0.000265	0.000486	CcSEcCtD
Mitotane—Headache—Methotrexate—urinary bladder cancer	0.000263	0.000483	CcSEcCtD
Mitotane—Asthenia—Doxorubicin—urinary bladder cancer	0.000261	0.000479	CcSEcCtD
Mitotane—Dizziness—Epirubicin—urinary bladder cancer	0.00026	0.000477	CcSEcCtD
Mitotane—CYP11B1—Metabolism—ENO2—urinary bladder cancer	0.000251	0.000874	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—HPGDS—urinary bladder cancer	0.000251	0.000874	CbGpPWpGaD
Mitotane—Vomiting—Epirubicin—urinary bladder cancer	0.00025	0.000459	CcSEcCtD
Mitotane—Nausea—Methotrexate—urinary bladder cancer	0.00025	0.000458	CcSEcCtD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000249	0.000869	CbGpPWpGaD
Mitotane—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000249	0.000457	CcSEcCtD
Mitotane—Rash—Epirubicin—urinary bladder cancer	0.000248	0.000455	CcSEcCtD
Mitotane—Dermatitis—Epirubicin—urinary bladder cancer	0.000248	0.000455	CcSEcCtD
Mitotane—Headache—Epirubicin—urinary bladder cancer	0.000246	0.000452	CcSEcCtD
Mitotane—FDX1—Metabolism—PTGS2—urinary bladder cancer	0.000245	0.000855	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—GSTT1—urinary bladder cancer	0.000243	0.000848	CbGpPWpGaD
Mitotane—Dizziness—Doxorubicin—urinary bladder cancer	0.000241	0.000442	CcSEcCtD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000239	0.000835	CbGpPWpGaD
Mitotane—Nausea—Epirubicin—urinary bladder cancer	0.000234	0.000429	CcSEcCtD
Mitotane—CYP11A1—Metabolism—RRM2—urinary bladder cancer	0.000231	0.000808	CbGpPWpGaD
Mitotane—Vomiting—Doxorubicin—urinary bladder cancer	0.000231	0.000425	CcSEcCtD
Mitotane—Rash—Doxorubicin—urinary bladder cancer	0.000229	0.000421	CcSEcCtD
Mitotane—Dermatitis—Doxorubicin—urinary bladder cancer	0.000229	0.000421	CcSEcCtD
Mitotane—Headache—Doxorubicin—urinary bladder cancer	0.000228	0.000418	CcSEcCtD
Mitotane—Nausea—Doxorubicin—urinary bladder cancer	0.000216	0.000397	CcSEcCtD
Mitotane—CYP11A1—Metabolism—HPGDS—urinary bladder cancer	0.000214	0.000748	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—ENO2—urinary bladder cancer	0.000214	0.000748	CbGpPWpGaD
Mitotane—FDX1—Metabolism—PTEN—urinary bladder cancer	0.000214	0.000745	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000213	0.000744	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—GSTT1—urinary bladder cancer	0.000208	0.000725	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000205	0.000714	CbGpPWpGaD
Mitotane—FDX1—Metabolism—EP300—urinary bladder cancer	0.000204	0.000711	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—NQO1—urinary bladder cancer	0.000202	0.000705	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000196	0.000684	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—NQO1—urinary bladder cancer	0.000173	0.000603	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000171	0.000596	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—GSTP1—urinary bladder cancer	0.000168	0.000588	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000168	0.000585	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000163	0.000569	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—TYMS—urinary bladder cancer	0.000157	0.000546	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—NCOR1—urinary bladder cancer	0.000155	0.00054	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—GSTM1—urinary bladder cancer	0.000155	0.00054	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—GPX1—urinary bladder cancer	0.000148	0.000517	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000146	0.00051	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—ERCC2—urinary bladder cancer	0.000146	0.000508	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—GSTP1—urinary bladder cancer	0.000144	0.000503	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000139	0.000486	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—MTHFR—urinary bladder cancer	0.000137	0.000477	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—TYMS—urinary bladder cancer	0.000134	0.000467	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—NCOR1—urinary bladder cancer	0.000132	0.000462	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—GSTM1—urinary bladder cancer	0.000132	0.000462	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—GPX1—urinary bladder cancer	0.000127	0.000442	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—ERCC2—urinary bladder cancer	0.000124	0.000434	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—MTHFR—urinary bladder cancer	0.000117	0.000408	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PPARG—urinary bladder cancer	0.000111	0.000387	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—CREBBP—urinary bladder cancer	0.000107	0.000372	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PPARG—urinary bladder cancer	9.49e-05	0.000331	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—CREBBP—urinary bladder cancer	9.12e-05	0.000318	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PTGS2—urinary bladder cancer	8.73e-05	0.000304	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PTEN—urinary bladder cancer	7.61e-05	0.000266	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PTGS2—urinary bladder cancer	7.46e-05	0.00026	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—EP300—urinary bladder cancer	7.26e-05	0.000253	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PTEN—urinary bladder cancer	6.51e-05	0.000227	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—EP300—urinary bladder cancer	6.21e-05	0.000217	CbGpPWpGaD
